ORGS momentum building .65+.05 developing cure for diabetes..novel approach
If you look at the longer term chart, this stock as been steadily rebuilding off of .50 following a dramatic runup in Oct to a buck following patent news.. Orgenesis Inc. (ORGS)-Other OTC 0.65 Up 0.05(8.33%) 11:20AM EST
Orgenesis Approved for EUR 2.015.000 Grant to Support Development of Its Type 1 Diabetes Program in EuropeMarketwired(Mon, Nov 24) How Orgenesis Hopes To Cure Type 1 DiabetesBenzinga(Mon, Nov 3) Orgenesis Receives Patent for Potential Cure for Type 1 DiabetesMarketwired(Wed, Oct 15)Note: Greenbackers will be profiling ORGS to our greater databases tomorrow pre mkt. CYRN deal sounds pretty significant.....Dips near 2.30 looking to reward near term
Patent Award for Diabetes Cure By Tobin Smith | December 9, 2014, 5:06pm GMT Orgenesis (ORGS) is a public company committed to curing type 1 diabetes with a breakthrough technology that combines cellular therapy and regenerative medicine – “Cellular Transdifferentiation.”
Professor Sarah Ferber and the research team at Orgenesis have successfully reprogrammedliver cells into fully functional Insulin Producing Cells (IPCs). They’ve had success curing diabetes in mice, and begin Phase 1 clinical trials in Type 1 diabetic patients in the next 12-15 months.
Unlike other diabetic treatments, the Orgenesis procedure is a cure for diabetics requiring insulin injections to regulate glucose in their blood stream.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.